VOA慢速英语2020 美国FDA批准雅培新推出的冠状病毒快速测试（在线收听）

The United States Food and Drug Administration (FDA) has approved a new coronavirus test that costs less than others and is simple to use.

美国食品和药品管理局批准了一项新的冠状病毒测试，它比其它测试的费用更低，并且易于使用。

The 15-minute test from Abbott Laboratories will sell for $5. It does not require special computer equipment to get results. The self-contained test is about the size of a credit card. It uses the same technology as some flu and pregnancy tests.

雅培实验室的这种15分钟测试的费用为5美元。它无需特殊计算机设备即可获得检测结果。这种独立检测试纸的尺寸大约是一张信用卡大小。它使用了与流感以及妊娠试验相同的技术。

The FDA noted that Abbott's test could be used in a doctor's office, emergency room or some schools. "Given the simple nature of this test, it is likely that these tests could be made broadly available," the FDA said.

美国食品和药品管理局指出，雅培的检测试纸可以在医生办公室、急诊室或是某些学校中使用。美国食品和药品管理局表示：“鉴于这种测试的性质简单，很可能会得到广泛应用。”

The agency also recently approved a saliva test from Yale University.

该机构最近还批准了耶鲁大学的一种唾液测试。

Both newly approved tests have limitations, like requiring medical administration.

两项新批准的测试都有局限性，例如都需要医疗手段。

Abbott's new test is called BinaxNOW. A health worker must carry out a nasal swab, like most older coronavirus tests. The Yale product does not require a swab, but only specialized laboratories can process the test.

雅培的新测试被称为BinaxNOW。像大多数以前的冠状病毒检测一样，医务人员必须进行鼻拭子检查。耶鲁大学的产品不需要拭子，但是只有专业实验室才能进行检测。

Quick tests like Abbott's, however, generally produce less exact results than those processed by laboratories. Abbott said BinaxNOW correctly finds coronavirus infection 97.1 percent of the time, and correctly finds a lack of infection 98.5 percent of the time.

然而雅培这样的快速测试所产生的结果通常不如实验室处理的结果准确。雅培表示，BinaxNOW诊断冠状病毒感染的准确率是97.1%，诊断未感染的准确率是98.5%。

In a statement, the FDA said Abbott's test may need to be confirmed with a lab test in some cases. The agency approved Abbott's test Wednesday night through an emergency use authorization process. It can be used only for patients with suspected COVID-19.

美国食品和药品管理局在一份声明中表示，在某些情况下，雅培的测试可能需要通过实验室检测加以确认。该机构通过紧急使用授权程序批准了雅培的测试。它仅可用于疑似新冠肺炎的患者。

The new tests come as schools and businesses around the U.S. are struggling to reopen with limited capability to test everyone for COVID-19.

这项新测试的诞生正值美国各地的学校和企业努力重新开放之际，当前检测能力有限，无法为每个人进行新冠肺炎检测。

Abbott announced that it will ship tens of millions of tests in September. The drug company plans to increase to 50 million tests a month at the beginning of October. Test takers can also show their results in a phone app and share them at workplaces or schools.

雅培宣布将于9月份交付数千万份检测试纸。这家制药公司计划在10月初将这种检测试纸的产量提高到每月5千万份。参加检测的人员还可以通过手机应用程序展示其检测结果，并在工作场所和学校中应用。

Most currently available COVID-19 tests have to be sent to a laboratory for results. Dr. Joseph Petrosino is a professor and chairman of Molecular Virology and Microbiology at Baylor College of Medicine in Texas. He said in the announcement from Abbott, "...you get a result right away, getting infectious people off the streets and into quarantine so they don't spread the virus."

目前可用的大多数新冠肺炎检测试纸都必须送往实验室以获得结果。约瑟夫·佩特罗西诺是德克萨斯州贝勒医学院分子病毒学和微生物学的教授兼系主任。他在雅培的公告中表示：“你会立即得到检测结果，将感染者从街头带到隔离区，这样他们就不会传播病毒。”

The U.S. is now testing about 690,000 people each day. That number is down from the 850,000 daily tests late last month. Many public health experts believe the U.S. will soon need to test a lot more people to find those who are infected, quarantine them and contain the virus.

美国现在每天检测大约69万人 。这个数字比上月底的每天检测85万人有所下降。许多公共卫生专家认为，美国很快将会需要对更多人进行检测，以便找出感染者，将其隔离并控制病毒传播。